Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Bayer Consolidates

Firm will close two major research labs in the U.S., eliminating 600 R&D positions

by Michael McCoy
November 13, 2006 | APPEARED IN VOLUME 84, ISSUE 46

Bayer will close two major U.S. research labs and eliminate about 600 positions, mostly in pharmaceutical R&D, as it advances its integration of the drugmaker Schering AG.

Bayer says it has worked out a structure for the new Bayer Schering Pharma R&D organization. Under this structure, research conducted at numerous sites worldwide will be consolidated into three major R&D centers, in Berlin and Wuppertal, Germany, and Berkeley, Calif.

The Berlin site will focus on diagnostic imaging, oncology, and gynecology/andrology. Wuppertal will be the base for cardiology research. Berkeley will continue its focus on protein-based drugs and become an anchor for work in immunology, inflammation, and hematology.

Bayer's U.S. research site in West Haven, Conn., will close, as will the Richmond, Calif., labs of Schering's Berlex subsidiary. The firm expects to complete the consolidation by mid-2007.

The restructuring around large R&D sites focused on specific therapeutic areas is reminiscent of the measures Pfizer took in 2003 in the wake of its acquisition of Pharmacia. That program affected more than 2,000 people in R&D.

Bayer says it will also restructure in Germany, where both Bayer and Schering are based, and in other countries. "It is not yet possible to issue concrete statements on headcounts and schedules," it says of these measures.



This article has been sent to the following recipient:

Leave A Comment

*Required to comment